当前位置: X-MOL 学术Mycoses › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The cost‐effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain
Mycoses ( IF 4.1 ) Pub Date : 2020-10-30 , DOI: 10.1111/myc.13189
José Ramón Azanza 1 , Santiago Grau 2 , Lourdes Vázquez 3 , Pablo Rebollo 4 , Carmen Peral 5 , Alejandra López-Ibáñez de Aldecoa 5 , Vanessa López-Gómez 6
Affiliation  

Invasive mould diseases are associated with high morbidity, mortality and economic impact. Its treatment is often started prior to differential pathogen diagnosis. Isavuconazole is approved for treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) when amphotericin‐B is not indicated.

中文翻译:

在西班牙进行病原体鉴别诊断之前,艾沙康唑与伏立康唑的成本效益相比,伏立康唑是侵袭性霉菌病患者的治疗标准

侵袭性霉菌病与高发病率、死亡率和经济影响有关。它的治疗通常在鉴别病原体诊断之前开始。艾沙康唑被批准用于治疗没有使用两性霉素 B 的侵袭性曲霉病 (IA) 和侵袭性毛霉菌病 (IM)。
更新日期:2020-10-30
down
wechat
bug